Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.
Estring: Reach for the Ring
For the treatment of moderate to severe symptoms of postmenopausal vaginal atrophyDemonstration Rings
Use this demonstration ring (containing no active ingredients) to show your patients the size and flexibility of Estring.
Insertion & Removal Guide
In addition to the Instructions for Use in the Patient Information, this guide will help your patients learn how to insert and remove Estring.
Patient Education Brochure
Help your patients learn more about postmenopausal vaginal atrophy and Estring with this informative brochure.
Savings Cards
Eligible patients pay as little as $45* for each of their next 4 Estring prescriptions.
*Terms and conditions apply. Savings are limited to $100 per prescription or the amount of your co-pay, whichever is less for each of 4 uses, up to a maximum annual savings of $400. Offer valid through December 31, 2022. This card is not valid for prescriptions that are reimbursed in whole or part by any state or federally funded prescription insurance program. This Savings Card is not health insurance. This Savings Card is only accepted at participating pharmacies. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. Please Click Here for full Terms and Conditions. To activate the Estring Savings Card or ask questions call 1‑800‑631‑1181.
- This Savings Card is not valid for prescriptions that are reimbursed, in whole or in part, by Medicaid, Medicare, Tricare, Veterans Affairs health care, or other federal or state health care programs (including any state prescription drug assistance programs) and the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
- Eligible patients may pay as little as $45 by using the Savings Card. The value of this Savings Card is limited to $100 per use or the amount of your co-pay, whichever is less for each of the 4 uses, up to a maximum annual savings of $400.
- This Savings Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
- You must deduct the value of this Savings Card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
- Patients who are enrolled in Medicare, Medicaid, or another state or federal health care program may use the Savings Card if paying for the prescription covered by the Savings Card is outside of their government insurance benefit, and no claim is submitted to Medicare, Medicaid or any federal or state health care program. Such patients must not apply any out-of-pocket expenses incurred using the Savings Card toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D true out-of-pocket (TrOOP) costs.
- You are responsible for reporting use of this Savings Card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Savings Card, as may be required. You should not use the Savings Card if your insurer or health plan prohibits use of manufacturer savings cards.
- You must be 18 years of age or older to redeem the Savings Card.
- This card is not valid where prohibited by law.
- Card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
- Card will be accepted only at participating pharmacies.
- This card is not health insurance.
- Offer good only in the U.S. and Puerto Rico.
- Card is limited to 1 per person during this offering period and is not transferable.
- The card may not be redeemed more than once per 90 days per patient.
- No other purchase is necessary.
- Data related to your redemption of the Savings Card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Savings Card redemptions and will not identify you.
- Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
- Offer expires 12/31/2022.
No membership fees apply. For help with the Estring Savings Card, call 1‑800‑631‑1181, or write: Pfizer Inc, 235 East 42nd Street, New York, NY 10017, or visit www.pfizer.com.
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) alone. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE combined with medroxyprogesterone acetate (MPA). In the absence of comparable data, these risks should be assumed to be similar for other dosage forms of estrogens.
The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen-alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women.
The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.
Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.
ESTRING should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active DVT, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (eg, stroke, myocardial infarction), or a history of these known conditions; anaphylactic reaction or known hypersensitivity to ESTRING; liver dysfunction or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders; known or suspected pregnancy.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid-binding globulin (TBG) levels.
The most frequently reported adverse events associated with ESTRING were headache, leukorrhea, back pain, genital moniliasis, upper respiratory tract infection, vaginitis, and vaginal discomfort/pain.
ESTRING is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
Please see Full Prescribing Information, including BOXED WARNING and Patient Information.
Indication
ESTRING is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.